Biolyst › CORTCORCEPT THERAPEUTICS INC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Dazucorilant in Patients With Amyotrophic Lateral Sclerosis on October 15, 2026. There are 5 upcoming events on record.
Cash runway is approximately 55.1 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 66 concluded trials, 88% reached completion rather than being terminated or withdrawn.
Track CORT alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open CORT in the tracker
Recent history
Date Event Type Phase
September 23, 2026
8-K filed: Leadership change, Reg FD disclosure Corporate
—
September 15, 2026
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies Trial Milestone
Phase 1/Phase 2
August 15, 2026
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers Trial Milestone
Phase 2
August 13, 2026
Evaluation of Miricorilant on Liver Fat in Patients With MASLD Trial Milestone
Phase 1
July 29, 2026
Quarterly results filed (8-K) Earnings
—
June 17, 2026
8-K filed: Other event Filing
—
June 3, 2026
8-K filed: Other event Filing
—
May 28, 2026
8-K filed: Leadership change Corporate
—
April 30, 2026
Quarterly results filed (8-K) Earnings
—
March 25, 2026
8-K filed: Other event Filing
—
March 3, 2026
Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects Trial Milestone
Phase 1
February 24, 2026
Quarterly results filed (8-K) Earnings
—
February 19, 2026
8-K filed: Other event Filing
—
February 13, 2026
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) Trial Milestone
Phase 2
January 22, 2026
8-K filed: Other event Filing
—
December 31, 2025
8-K filed: Other event Filing
—
November 4, 2025
Quarterly results filed (8-K) Earnings
—
October 6, 2025
8-K filed: Leadership change Corporate
—
September 10, 2025
8-K filed: Other event Filing
—
July 31, 2025
Quarterly results filed (8-K) Earnings
—
July 14, 2025
8-K filed: Other event Filing
—
May 5, 2025
Quarterly results filed (8-K) Earnings
—
March 31, 2025
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer Trial Milestone
Phase 3
December 9, 2024
Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant Trial Milestone
Phase 1
November 19, 2024
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST) Trial Milestone
Phase 4
September 19, 2024
A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas Trial Milestone
Phase 3
September 13, 2024
Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant Trial Milestone
Phase 1
August 2, 2024
Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants Trial Milestone
Phase 1
April 8, 2024
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome Trial Milestone
Phase 3
January 29, 2024
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) Trial Milestone
Phase 1
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.